Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

SHIRE PLC: Guidance Update


Guidance Update

Dublin, Ireland - January 8, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Angus Russell, Chief Executive Officer of Shire, will address investors today at the JP Morgan Healthcare Conference in San Francisco. In his address he will confirm that Shire expects to deliver double digit full year earnings growth for 2012, and looking ahead, Shire is now increasingly confident of meeting current consensus earnings expectations(1) for 2013.

Angus' presentation will be webcast live today, at 11:00 AM PST/2:00 PM EST/7: 00 PM GMT

Investors can access the live webcast here http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=SHP.L

(1) Based on the most recent consensus estimates compiled by Consensus Forecast Ltd, as of the date of this press release, of $6.69 Non GAAP diluted earnings per ADS for the year ended 31 December 2013, included on Shire's website (http: //www.shire.com/shireplc/en/investors/forecasts).

For further information please contact:

Investor Relations

Eric Rojas erojas@shire.com +1 781 482 0999

Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157

Media

Jessica Mann jmann@shire.com +44 1256 894 280

Gwen Fisher gfisher@shire.com +1 484 595 9836

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

* Behavioral Health and Gastro Intestinal conditions


      * Rare Diseases
      * Regenerative Medicine
    as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995

Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, the Company's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of the Company's products; the Company's
ability to manufacture its products in sufficient quantities to meet demand;
the impact of competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other intellectual
property rights relating to its products; the Company's ability to obtain and
maintain government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com

END

-0- Jan/08/2013 17:00 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement